Retrospective Study
Copyright ©The Author(s) 2021.
World J Hepatol. Oct 27, 2021; 13(10): 1428-1438
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1428
Table 1 Clinical and laboratory characteristics in Wilson’s disease children with acute liver failure and hemolytic anemia
Parameter
All (n = 51)
ALF and hemolytic anemia(8 pts)
Other clinical forms(43 pts)
P value
Females, n (%)26 (50.98)8 (100)18 (41.86)0.00252
Mean age (yr)12.36 ± 3.7414.59 ± 2.2111.59 ± 3.790.03598
ALT (IU/L)131.54 ± 119.6987.38 ±154.07142.24 ± 110. 040.24969
AST (IU/L)125.05 ± 88.7378.62 ± 47.44136.30 ± 93.160.09950
TB (mg/dL)5.41 ± 12.9322.55 ± 21.950.99 ± 0.950.000002
DB (mg/dL)4.20 ± 11.5618.84 ± 20.400.42 ± 0.510.000007
GGT (IU/L)83.54 ± 43.4497.71 ± 57.1480.44 ± 40.330.34731
WBC (mm3)8568 ± 736014838 ± 141856666 ± 17990.00415
Hb (g/dL)12.15 ±2.967.4 ± 2.3913.51 ± 1.220.000000
PLT (mm3)253306 ±125421164875 ± 74043278571 ± 1264550.02142
INR2.94 ± 6.377.53 ± 11.341.18 ± 0.270.01359
KF ring, n (%) 9 (17.65)3 (37.50)6 (13.95)0.10868
Ceruloplasmin (mg/dL)9.81 ± 6.1187.98 ± 5.7710.11 ± 6.190.39976
Urinary copper (μg/24 h)648.94 ± 1093.902 236.33 ± 2 174.46384.38 ± 455.040.000006
Outcome, n (%)0.00121
Survivors47 (92.16)5 (62.50)42 (97.67)
Transplanted2 (3.92)2 (25.00)0
Deceased2 (3.92)1 (12.50)1 (2.33)
Table 2 Variants of ATP7B gene in children with hemolytic anemia and acute liver failure
Variants

Hemolytic Anemia + ALF (8 patients)
Other clinical forms (44 patients)
P value
p.Trp939Cys (c.2817G>T)5 homozygotes6 (42.86%)4 (4.55%)0.0000
p.Lys844Ter (c.2530A>T)1 homozygotes4 (28.57%)1 (1.14%)0.0000
3 heterozygotes
p.Gly1341Asp (c.4021G>A)10 homozygotes4 (28.57%)23 (26.14%)0.8482
7 heterozygotes
p.His1069Gln (c.3207A>G)12 homozygotes039 (44.32%)0.0015
15 heterozygotes
Other variants1 homozygotes2 (14.29%)19 (21.59%)0.5304
19 heterozygotes
Total alleles14 (100%)88 (100%)
Table 3 Data regarding the patients evaluated for the HSD17B13:TA variant

All
HSD17B13 genotype
T/T
TA/T
TA/TA
n (%)3319 (57.58)12 (36.36)2 (6.06)
Females, n (%)161150
Mean age (yr)11.67 ± 3.1211.09 ± 3.4512.14 ± 2.2514.70 ± 3.24
Clinical presentation, n (%)
ALF and/or hemolytic anemia7 (21.21)5 (71.43)2 (28.57)0
Less severe hepatic forms26 (78.79)14 (53.85)10 (38.46)2 (7.69)
ATP7B variant
p.His1069Gln (c.3206A>G)/p.His1069Gln (c.3206A>G)5230
p.His1069Gln (c.3206A>G)/p.Gly1341Asp (c.4021G>A)6330
p.His1069Gln (c.3206A>G)/other7430
p.Gly1341Asp (c.4021G>A)/p.Gly1341Asp (c.4021G>A)7322
p.Trp939Cys (c.2817G>T)/p.Trp939Cys (c.2817G>T)4400
p.Trp939Cys (c.2817G>T)/other1100
p.Lys844Ter (c.2530A>T)/p.Lys844Ter (c.2530A>T)1100
p.Lys844Ter (c.2530A>T)/ other2110